Document Detail

Can malaria chemoprophylaxis be restricted to first pregnancies?
MedLine Citation:
PMID:  7886770     Owner:  NLM     Status:  MEDLINE    
The harmful effects of malaria are most pronounced during first pregnancies and chemoprophylaxis is most effective when given at this time. However, restriction of chemoprophylaxis to first pregnancies might lead to enhanced susceptibility to malaria during second pregnancies. We have investigated this possibility by studying the outcome of second pregnancies in 165 Gambian women who had received either malaria chemoprophylaxis with Maloprim or placebo during their first pregnancy. Many of these primigravidae did not present until the third trimester of pregnancy so that some are likely to have experienced a malaria infection before they started medication. The prevalence of malaria infection of the blood and of the placenta during second pregnancies was similar in women who had received chemoprophylaxis during their first pregnancy and in those who had not, and the mean birth weights of babies born to women in each group were almost identical. Thus, in areas where the epidemiology of malaria is similar to that of The Gambia and where most women present relatively late in pregnancy, it may be possible to restrict malaria chemoprophylaxis to first pregnancies with consequent savings in cost and a reduction in drug pressure on Plasmodium falciparum.
A M Greenwood; C Menendez; P L Alonso; S Jaffar; P Langerock; S Lulat; J Todd; B M'Boge; N Francis; B M Greenwood
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transactions of the Royal Society of Tropical Medicine and Hygiene     Volume:  88     ISSN:  0035-9203     ISO Abbreviation:  Trans. R. Soc. Trop. Med. Hyg.     Publication Date:    1994 Nov-Dec
Date Detail:
Created Date:  1995-04-13     Completed Date:  1995-04-13     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7506129     Medline TA:  Trans R Soc Trop Med Hyg     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  681-2     Citation Subset:  IM    
Medical Research Council Laboratories, Fajara, Banjul, The Gambia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimalarials / therapeutic use*
Birth Weight
Chronic Disease
Dapsone / therapeutic use*
Drug Combinations
Follow-Up Studies
Infant, Newborn
Malaria / pathology,  prevention & control*
Placenta / pathology
Pregnancy Complications, Parasitic / prevention & control*
Pregnancy Outcome
Pyrimethamine / therapeutic use*
Reg. No./Substance:
0/Antimalarials; 0/Drug Combinations; 37357-69-0/Maloprim; 58-14-0/Pyrimethamine; 80-08-0/Dapsone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dengue haemorrhagic fever in the state of Rio de Janeiro, Brazil: a study of 56 confirmed cases.
Next Document:  In vitro drug interaction between amantadine and classical antimalarial drugs in Plasmodium falcipar...